All News

From newsworthy moments to groundbreaking research, these are the most popular articles published on Pharmacy Times® during 2019.

Officials with the FDA have approved olaparib (Lynparza, AstraZeneca and Merck) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

Deeb Eid, PharmD, is creator of the Pharmacy Universe podcast on Spreaker. An associate professor and experiential coordinator at Ferris State University College of Pharmacy in Grand Rapids, MI, Eid speaks with pharmacy industry guests to educate and engage listeners about the profession.

Officials with the FDA have approved Eisai’s lemborexant (Dayvigo) 5 mg and 10 mg for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

The applications for the first generics of apixaban (Eliquis, Bristol-Meyers Squibb) tablets were approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation

Ubrogepant is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved by the agency for the acute treatment of migraine.